Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm study of crovalimab in pediatric aHUS
jRCT2041210086Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of crovalimab in atypical hemolytic uremic syndrome (aHUS), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Complete TMA response rate. Started Jul 2022; status: active, not recruiting.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on jRCT2041210086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210086.